Overview

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Ritonavir